Aminoglycoside-associated hypomagnesaemia in children with cystic fibrosis.
Hypomagnesaemia in children with cystic fibrosis (CF) is under-recognized. We report a child with CF who developed significant hypomagnesaemia following intravenous (i.v.) treatment with aminoglycosides for exacerbations of Pseudomonas aeruginosa infection. Three additional cases have also been observed. Investigations in two patients have revealed excessive renal loss of magnesium. It is postulated that renal tubular damage secondary to the cumulative effects of repeated courses of aminoglycosides resulted in hypomagnesaemia, and we suggest screening for this problem by monitoring serum magnesium regularly in all patients with CF receiving multiple courses of aminoglycosides.
Akbar
A
A
Paediatric Respiratory and Cystic Fibrosis Unit, The Birmingham Children's Hospital NHS Trust, UK.
Rees
J H
JH
Nyamugunduru
G
G
English
M W
MW
Spencer
D A
DA
Weller
P H
PH
D000208:Acute Disease; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000150:complications*; D005260:Female; D006801:Humans; D007684:Kidney Tubules / Q000187:drug effects; D008274:Magnesium / Q000097:blood; D008275:Magnesium Deficiency / Q000139:chemically induced*; D011552:Pseudomonas Infections / Q000150:complications* / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa; D014031:Tobramycin / Q000009:adverse effects*
D000900:Anti-Bacterial Agents; D008274:Magnesium; D014031:Tobramycin